JP4545928B2 - 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 - Google Patents

第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 Download PDF

Info

Publication number
JP4545928B2
JP4545928B2 JP2000545506A JP2000545506A JP4545928B2 JP 4545928 B2 JP4545928 B2 JP 4545928B2 JP 2000545506 A JP2000545506 A JP 2000545506A JP 2000545506 A JP2000545506 A JP 2000545506A JP 4545928 B2 JP4545928 B2 JP 4545928B2
Authority
JP
Japan
Prior art keywords
fviii
pharmaceutical composition
colloidal particles
lipid
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000545506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512947A (ja
JP2002512947A5 (https=
Inventor
バル、モーシェ
バー、リリアナ
ヌーア、イスラエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zilip Pharma BV
Original Assignee
Zilip Pharma BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zilip Pharma BV filed Critical Zilip Pharma BV
Publication of JP2002512947A publication Critical patent/JP2002512947A/ja
Publication of JP2002512947A5 publication Critical patent/JP2002512947A5/ja
Application granted granted Critical
Publication of JP4545928B2 publication Critical patent/JP4545928B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2000545506A 1998-04-27 1999-04-23 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 Expired - Fee Related JP4545928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL124224 1998-04-27
IL12422498 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (3)

Publication Number Publication Date
JP2002512947A JP2002512947A (ja) 2002-05-08
JP2002512947A5 JP2002512947A5 (https=) 2006-01-05
JP4545928B2 true JP4545928B2 (ja) 2010-09-15

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000545506A Expired - Fee Related JP4545928B2 (ja) 1998-04-27 1999-04-23 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物

Country Status (12)

Country Link
US (2) US6593294B1 (https=)
EP (1) EP1079805B1 (https=)
JP (1) JP4545928B2 (https=)
AT (1) ATE283034T1 (https=)
AU (1) AU747391B2 (https=)
BR (1) BR9909978A (https=)
CA (1) CA2329768C (https=)
DE (1) DE69922189T2 (https=)
ES (1) ES2233036T3 (https=)
MX (1) MXPA00010241A (https=)
PT (1) PT1079805E (https=)
WO (1) WO1999055306A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1536843B1 (en) * 2002-07-02 2010-12-22 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
EP1633440B1 (en) * 2003-04-15 2008-05-14 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
CA2534565C (en) * 2003-08-05 2012-06-19 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
WO2005079185A2 (en) * 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
EP1713446B1 (en) * 2004-01-23 2010-12-01 Camurus Ab Ternary non-lamellar lipid compositions
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
CN101304757A (zh) * 2005-06-29 2008-11-12 纽约州立大学研究基金会 免疫原性较低的蛋白质-脂质复合物的组合物和方法
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
DK2299953T3 (en) 2008-07-14 2017-06-19 Polypid Ltd CARBON COMPOSITION FOR MEDICINAL PRODUCTS WITH CONTINUOUS EXPOSURE
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
IN2012DN00570A (https=) 2009-07-14 2015-06-12 Polypid Ltd
EP2470287A4 (en) 2009-08-28 2015-01-21 Univ Columbia SYSTEMS, METHODS AND DEVICES FOR PRODUCING GAS-FILLED MICROBUBBLES
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
CN102892406B (zh) 2010-01-19 2015-04-08 波利皮得有限公司 缓释核酸基质组合物
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
WO2016188905A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
RU2017145014A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
ATE283034T1 (de) 2004-12-15
DE69922189D1 (de) 2004-12-30
US6930087B2 (en) 2005-08-16
EP1079805B1 (en) 2004-11-24
JP2002512947A (ja) 2002-05-08
PT1079805E (pt) 2005-03-31
US20030134778A1 (en) 2003-07-17
EP1079805A1 (en) 2001-03-07
CA2329768C (en) 2008-06-10
ES2233036T3 (es) 2005-06-01
CA2329768A1 (en) 1999-11-04
DE69922189T2 (de) 2005-11-10
BR9909978A (pt) 2000-12-26
AU747391B2 (en) 2002-05-16
WO1999055306A1 (en) 1999-11-04
MXPA00010241A (es) 2004-09-06
US6593294B1 (en) 2003-07-15
AU3441499A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
JP4545928B2 (ja) 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
JP2024532164A (ja) 血友病ａの治療における使用のための修飾コロイド粒子
CN1774281B (zh) 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
US20030232075A1 (en) Compositions for producing factor Xa
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
IL139053A (en) Pharmaceutical composition comprising factor VIII and neutral colloidal particles
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
Ramani et al. Preclinical Evaluation of PEGylated Liposomal-Recombinant Human FVIII in a Murine Model of Hemophilia A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050714

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100701

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees